Search results
Showing 16 to 30 of 163 results for fibrosis
This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.
Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)
Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.
Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.
This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.
This quality standard covers diagnosing and managing cystic fibrosis in infants, children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS168Show all sections
treatment for idiopathic pulmonary fibrosis:- Is anti-reflux therapy an effective treatment for idiopathic pulmonary...
outcomes in idiopathic pulmonary fibrosis:- Does ambulatory oxygen improve outcomes in idiopathic pulmonary fibrosis? Any...
MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.
All NICE products on cystic fibrosis. Includes any guidance, advice and quality standards.
with idiopathic pulmonary fibrosis:- Does pulmonary rehabilitation improve outcomes for people with idiopathic pulmonary...
study (a sub-study). Some people need ERT after Intrabeam (see page 3). Fibrosis (thickening and stiffening of the breast tissue) is the...
NG49/5 Question Pharmacological therapy for advanced liver fibrosis in children and young people:- What is the clinical and cost...
Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)
Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults.
In development Reference number: GID-HTE10084 Expected publication date: 21 October 2026
advanced liver fibrosis in children and young people:- Which non-invasive tests most accurately diagnose NAFLD and advanced liver...